Targeting KRAS(G12C) in colorectal cancer: the beginning of a new era

RAS mutation is considered one of the most relevant oncogenic drivers in human cancers. Unfortunately, for more than three decades, RAS has been considered an undruggable target. Recently, the discovery of selective and potent KRAS(G12C) inhibitors represented a light at the end of the tunnel. Indee...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciardiello, D., Maiorano, B.A., Martinelli, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800313/
https://www.ncbi.nlm.nih.gov/pubmed/36549128
http://dx.doi.org/10.1016/j.esmoop.2022.100745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800313/
https://www.ncbi.nlm.nih.gov/pubmed/36549128
http://dx.doi.org/10.1016/j.esmoop.2022.100745

Ejemplares similares